Which has better valuation & earnings, KRYS or QURE?

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 25.00 $204.83M $7.98 41.19 uniQure $16.10M 99.50 -$198.97M -$4.01 N/A

Is KRYS or QURE more profitable?

Krystal Biotech has a net margin of 54.82% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.34% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% uniQure -1,350.73% -111.96% -29.01%

Does the media favor KRYS or QURE?

In the previous week, uniQure had 36 more articles in the media than Krystal Biotech. MarketBeat recorded 38 mentions for uniQure and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat uniQure's score of 0.18 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 6 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor QURE or KYMR?

In the previous week, uniQure had 34 more articles in the media than Kymera Therapeutics. MarketBeat recorded 38 mentions for uniQure and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat uniQure's score of 0.18 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 6 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor QURE or ARWR?

In the previous week, uniQure had 32 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 38 mentions for uniQure and 6 mentions for Arrowhead Pharmaceuticals. uniQure's average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 6 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, IBRX or QURE?

uniQure has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 97.91 -$351.40M -$0.97 N/A uniQure $16.10M 99.50 -$198.97M -$4.01 N/A

Is IBRX or QURE more profitable?

ImmunityBio has a net margin of -598.55% compared to uniQure's net margin of -1,350.73%. ImmunityBio's return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% uniQure -1,350.73% -111.96% -29.01%

Does the media favor IBRX or QURE?

In the previous week, uniQure had 29 more articles in the media than ImmunityBio. MarketBeat recorded 38 mentions for uniQure and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.67 beat uniQure's score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 6 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer QURE or PTGX?

In the previous week, uniQure had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 38 mentions for uniQure and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat uniQure's score of 0.18 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 6 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$23.46 +0.09 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$23.22 -0.24 (-1.04%)

As of 07:40 PM Eastern

Compare

QURE vs. KRYS, KYMR, ARWR, IBRX, and PTGX

Should you buy uniQure stock or one of its competitors? uniQure's main competitors and comparable companies include Krystal Biotech (KRYS), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does uniQure compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Krystal Biotech presently has a consensus target price of $377.20, indicating a potential upside of 14.75%. uniQure has a consensus target price of $56.64, indicating a potential upside of 145.26%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

In the previous week, uniQure had 36 more articles in the media than Krystal Biotech. MarketBeat recorded 38 mentions for uniQure and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat uniQure's score of 0.18 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	6 Very Positive mention(s)	7 Positive mention(s)	19 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a net margin of 54.82% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.34% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
uniQure	-1,350.73%	-111.96%	-29.01%

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.00	$204.83M	$7.98	41.19
uniQure	$16.10M	99.50	-$198.97M	-$4.01	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, uniQure has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Summary

Krystal Biotech beats uniQure on 12 of the 17 factors compared between the two stocks.

How does uniQure compare to Kymera Therapeutics?

uniQure (NASDAQ:QURE) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, uniQure had 34 more articles in the media than Kymera Therapeutics. MarketBeat recorded 38 mentions for uniQure and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat uniQure's score of 0.18 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	6 Very Positive mention(s)	7 Positive mention(s)	19 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has a net margin of -285.33% compared to uniQure's net margin of -1,350.73%. Kymera Therapeutics' return on equity of -21.22% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

uniQure has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	99.50	-$198.97M	-$4.01	N/A
Kymera Therapeutics	$39.21M	231.72	-$311.35M	-$3.24	N/A

uniQure has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

uniQure currently has a consensus price target of $56.64, suggesting a potential upside of 145.26%. Kymera Therapeutics has a consensus price target of $133.21, suggesting a potential upside of 21.91%. Given uniQure's higher probable upside, research analysts plainly believe uniQure is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kymera Therapeutics beats uniQure on 11 of the 16 factors compared between the two stocks.

How does uniQure compare to Arrowhead Pharmaceuticals?

uniQure (NASDAQ:QURE) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Arrowhead Pharmaceuticals has higher revenue and earnings than uniQure. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	99.50	-$198.97M	-$4.01	N/A
Arrowhead Pharmaceuticals	$829.45M	11.00	-$1.63M	-$2.25	N/A

In the previous week, uniQure had 32 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 38 mentions for uniQure and 6 mentions for Arrowhead Pharmaceuticals. uniQure's average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	6 Very Positive mention(s)	7 Positive mention(s)	19 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to uniQure's net margin of -1,350.73%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

uniQure presently has a consensus target price of $56.64, suggesting a potential upside of 145.26%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, suggesting a potential upside of 51.71%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

78.8% of uniQure shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

uniQure has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Summary

uniQure beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does uniQure compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 35.68%. uniQure has a consensus price target of $56.64, suggesting a potential upside of 145.26%. Given uniQure's higher possible upside, analysts plainly believe uniQure is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

In the previous week, uniQure had 29 more articles in the media than ImmunityBio. MarketBeat recorded 38 mentions for uniQure and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.67 beat uniQure's score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	6 Very Positive mention(s)	7 Positive mention(s)	19 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

uniQure has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	97.91	-$351.40M	-$0.97	N/A
uniQure	$16.10M	99.50	-$198.97M	-$4.01	N/A

ImmunityBio has a net margin of -598.55% compared to uniQure's net margin of -1,350.73%. ImmunityBio's return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
uniQure	-1,350.73%	-111.96%	-29.01%

ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, uniQure has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

uniQure beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to Protagonist Therapeutics?

uniQure (NASDAQ:QURE) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

uniQure presently has a consensus target price of $56.64, suggesting a potential upside of 145.26%. Protagonist Therapeutics has a consensus target price of $147.13, suggesting a potential upside of 5.33%. Given uniQure's higher probable upside, research analysts plainly believe uniQure is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, uniQure had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 38 mentions for uniQure and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat uniQure's score of 0.18 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	6 Very Positive mention(s)	7 Positive mention(s)	19 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	99.50	-$198.97M	-$4.01	N/A
Protagonist Therapeutics	$46.02M	196.42	-$130.15M	$1.03	135.62

Protagonist Therapeutics has a net margin of 29.40% compared to uniQure's net margin of -1,350.73%. Protagonist Therapeutics' return on equity of 12.03% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Protagonist Therapeutics	29.40%	12.03%	11.23%

uniQure has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

78.8% of uniQure shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats uniQure on 14 of the 17 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.62B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.77%
P/E Ratio	-5.85	12.93	273.67	26.04
Price / Sales	101.08	1,308.36	612.51	90.64
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	7.35	16.63	10.92	6.30
Net Income	-$198.97M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-38.63%	-3.05%	-2.11%	-1.67%
1 Month Performance	-49.25%	-10.75%	-6.34%	-3.94%
1 Year Performance	-56.95%	21.11%	8.81%	2.77%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.9037 of 5 stars	$23.46 +0.4%	$56.64 +141.4%	-57.5%	$1.62B	$16.10M	N/A	221	Analyst Forecast Options Volume
KRYS Krystal Biotech	4.3034 of 5 stars	$345.82 +0.2%	$377.20 +9.1%	+81.1%	$10.21B	$389.13M	43.34	295
KYMR Kymera Therapeutics	2.1243 of 5 stars	$111.95 -3.3%	$133.21 +19.0%	+101.5%	$9.63B	$39.21M	N/A	273	Insider Trade
ARWR Arrowhead Pharmaceuticals	2.9315 of 5 stars	$65.92 -0.2%	$98.31 +49.1%	+85.1%	$9.31B	$829.45M	N/A	711
IBRX ImmunityBio	2.8297 of 5 stars	$8.44 -2.3%	$14.20 +68.2%	+274.2%	$9.16B	$113.29M	N/A	691

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. KRYS, KYMR, ARWR, IBRX, and PTGX

How does uniQure compare to Krystal Biotech?

Summary

How does uniQure compare to Kymera Therapeutics?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Summary

How does uniQure compare to ImmunityBio?

Summary

How does uniQure compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. KRYS, KYMR, ARWR, IBRX, and PTGX

How does uniQure compare to Krystal Biotech?

Do analysts recommend KRYS or QURE?

Does the media favor KRYS or QURE?

Is KRYS or QURE more profitable?

Which has better valuation & earnings, KRYS or QURE?

Do institutionals & insiders believe in KRYS or QURE?

Which has more risk and volatility, KRYS or QURE?

Summary

How does uniQure compare to Kymera Therapeutics?

Do insiders & institutionals have more ownership in QURE or KYMR?

Does the media favor QURE or KYMR?

Is QURE or KYMR more profitable?

Which has better earnings and valuation, QURE or KYMR?

Which has more risk & volatility, QURE or KYMR?

Do analysts rate QURE or KYMR?

Summary

How does uniQure compare to Arrowhead Pharmaceuticals?

Which has higher valuation and earnings, QURE or ARWR?

Does the media favor QURE or ARWR?

Is QURE or ARWR more profitable?

Do analysts rate QURE or ARWR?

Do insiders and institutionals have more ownership in QURE or ARWR?

Which has more risk and volatility, QURE or ARWR?

Summary

How does uniQure compare to ImmunityBio?

Do analysts rate IBRX or QURE?

Does the media favor IBRX or QURE?

Which has preferable earnings & valuation, IBRX or QURE?

Is IBRX or QURE more profitable?

Which has more volatility and risk, IBRX or QURE?

Do institutionals & insiders hold more shares of IBRX or QURE?

Summary

How does uniQure compare to Protagonist Therapeutics?

Do analysts rate QURE or PTGX?

Does the media prefer QURE or PTGX?

Which has higher earnings and valuation, QURE or PTGX?

Is QURE or PTGX more profitable?

Which has more risk & volatility, QURE or PTGX?

Do insiders & institutionals hold more shares of QURE or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools